Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves MSD’s Keytruda combinations for MIBC
KEYNOTE-B15 enrolled 808 patients and compared pembrolizumab plus enfortumab vedotin-ejfv with standard chemotherapy and surgery. Credit: Sai Thaw Kyar / Shutterstock.com.
KEYNOTE-B15 enrolled 808 patients and compared pembrolizumab plus enfortumab vedotin-ejfv with standard chemotherapy and surgery. Credit: Sai Thaw Kyar / Shutterstock.com.